The catalepsy test: Its ups and downs.

Abstract

The typical catalepsy test consists of placing an animal into an unusual posture and recording the time taken to correct this posture. This time is regarded as an index of the intensity of catalepsy. Catalepsy is a robust behavior, and the lack of standardization does not usually hinder its actual detection. However, the intensity of the cataleptic effect is influenced by minor methodological differences, and thus interpretation and comparison of results across laboratories are difficult. The behavioral catalepsy test can use any of several different apparatus, including wire grids, parallel bars, platforms, or pegs, to situate the animals in unusual positions. The most common, however, is the "bar test," and despite its wide use in psychopharmacological research, even parameters of this test are not standardized. The present article reviews the wide variety of parameters chosen by investigators that measure catalepsy. The methodological issues of repeated testing, scaling of scores, apparatus, animal weight, maximal test duration, behavioral criteria, and other influences are discussed. In addition, a brief review of the neuropharmacological basis of catalepsy is also included. Finally, it is argued that a universal, standardized bar test be adopted by researchers. New data on a novel automated bar test in the Digiscan Activity Monitoring System is presented.

Cites (2)

1. Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
   Creese, Ian, Burt, David R., Snyder, Solomon H. · 1976 · Science
2. Antipsychotic drug doses and neuroleptic/dopamine receptors
   SEEMAN, P., LEE, T., CHAU-WONG, M., WONG, K. · 1976 · Nature

Show all 2 references

Cited by (5)

1. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight
   Revel, F G, Moreau, J-L, Pouzet, B, Mory, R, Bradaia, A, Buchy, D, Metzler, V, Chaboz, S, Groebke Zbinden, K, Galley, G et al. · 2013 · Molecular Psychiatry
2. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
   Moreira, Fabrício A., Guimarães, Francisco S. · 2005 · European Journal of Pharmacology
3. Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
   Esposito, Elisabetta, Fantin, Martina, Marti, Matteo, Drechsler, Markus, Paccamiccio, Lydia, Mariani, Paolo, Sivieri, Elisa, Lain, Francesco, Menegatti, Enea, Morari, Michele et al. · 2008 · Pharmaceutical Research
4. Preclinical Behavioral Models for Predicting Antipsychotic Activity
   Castagné, Vincent, Moser, Paul C., Porsolt, Roger D. · 2009 · Advances in Pharmacology
5. Modulation by female sex hormones of the cannabinoid-induced catalepsy and analgesia in ovariectomized mice.
   Kalbasi Anaraki, Dina, Sianati, Setareh, Sadeghi, Mahsa, Ghasemi, Mehdi, Javadi, Parvin, Ejtemaei Mehr, Shahram, Dehpour, Ahmad Reza · 2008 · European Journal of Pharmacology

See all 375